Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Even at the beginning, many people report a noticeable shift in how they interact with food
Tirzepatide carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies, though this risk has not been confirmed in humans
The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes
Continuous IGF-1 receptor stimulation beyond six weeks triggers adaptive receptor downregulation the cell reduces surface IGF-1 receptor density to prevent overstimulation
Always talk to your healthcare provider before combining therapies
Pros Cons Compounded version only available during FDA-confirmed shortages Compounded version must be drawn with syringe and injected manually Possible side effects: nausea, GI discomfort, headache, fatigue Not covered by insurance if compounded
